Thierry Brue researcher
Brue, Thierry
Brue, Thierry, 19..-....
VIAF ID: 17346173 (Personal)
Permalink: http://viaf.org/viaf/17346173
Preferred Forms
- 200 _ | ‡a Brue ‡b Thierry
- 100 1 _ ‡a Brue, Thierry
-
- 100 1 _ ‡a Brue, Thierry
- 100 1 _ ‡a Brue, Thierry, ‡d 19..-....
- 100 0 _ ‡a Thierry Brue ‡c researcher
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
115 patients acromégales opérés entre 1997 et 2007 au CHU de la Timone à Marseille : Devenir à court et long terme et facteurs pronostiques de rémission | |
Apport du test couplé DExaméthasone-desmopressine dans la surveillance des patients traités par chirurgie transphénoïdale pour une maladie de Cushing | |
Bases moléculaires des hypopituitarismes congénitaux | |
The coupled dexamethasone-desmopressin text, a useful additional tool to adapt follow-up to the risk of postoperative recurrence in Cushing's disease. | |
Diabète | |
Endocrinologie, diabétologie, nutrition | |
Etiologies héréditaires et somatiques des adénomes hypophysaires : étude du gène Men1 et du locus Gnas | |
Homeodomain transcription factors : from mouse development to human hypopituitarism. | |
Hyperprarathyroïdie primaire et imagerie discordante ou négative : Peut-on éviter l'exploration cervicale bilatérale ? | |
HYPOPHYSITES LYMPHOCYTAIRES : ETUDE MULTICENTRIQUE DANS LE CADRE DU CLUB FRANCAIS DE L'HYPOPHYSE (DES ENDOCRINOLOGIE ET METABOLISMES) | |
Macroprolactinemia revisited: a study on 106 patients | |
La macroprolactinémie : implications cliniques et biologiques actuelles | |
MANAGEMENT OF ENDOCRINE DISEASE: Management of Cushing's syndrome during pregnancy: solved and unsolved questions. | |
Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. | |
Markers of tumor invasion are major predictive factors for the long-term outcome of corticotroph microadenomas treated by transsphenoidal adenomectomy | |
LES METASTASES HYPOPHYSAIRES : PRESENTATIONS CLINIQUES ET CONDUITE A TENIR | |
Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes. | |
A monocentric experience of growth hormone replacement therapy in adult patients | |
MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. | |
A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues. | |
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. | |
New regulatory mechanisms in the growth of endocrine tumors : digestive neuroendocrine tumors, pitiutary adenomas | |
[Non thyroidal illnesses | |
[Noonan's syndrome and growth hormone treatment] | |
Nouveaux mécanismes de régulation de la croissance des tumeurs endocrines : tumeurs neuroendocrines digestives, adénomes hypophysaires. | |
An observational study on adrenal insufficiency in a French tertiary centre: Real life versus theory | |
Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients | |
Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study | |
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures | |
Pathophynological mechanisms in congenital multiple hypopituitarisms. | |
Pattern of prolactin diurnal secretion in normal humans: evidence for nonlinear dynamics. | |
Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets | |
Phenotypic Homogeneity and Genotypic Variability in a Large Series of Congenital Isolated ACTH-Deficiency Patients withTPITGene Mutations | |
Pilot Neonatal Screening Program for Central Congenital Hypothyroidism: Evidence of Significant Detection. | |
[Pituitary adenomas: an earlier diagnosis] | |
Pituitary apoplexy after somatostatin analogue administration: coincidental or causative? | |
A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins | |
Pituitary gland: Gamma Knife for Cushing disease - time for a reappraisal? | |
Pituitary hormone deficiencies due to transcription factor gene alterations. | |
Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. | |
Pituitary stem cell update and potential implications for treating hypopituitarism | |
Pituitary tumor syndrome and hyperprolactinemia in peripheral hypothyroidism | |
PITX2 AND PITX1 regulate thyrotroph function and response to hypothyroidism | |
Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly | |
Preoperative medical treatment in Cushing's syndrome. Frequency of use and its impact on postoperative assessment. Data from ERCUSYN. | |
Prevalence of KISS1 Receptor mutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. | |
Prise en charge des patientes atteintes d'un hypogonadisme hypogonadotrope congénital | |
Le profil des hormones de la régulation de l'appétit dans la maigreur | |
Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up | |
PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. | |
[Prolactin-secreting adenoma] | |
LA PROLACTINE HUMAINE, ASPECTS PHYSIOPATHOLOGIQUES ; RESISTANCE DES PROLACTINOMES A LA BROMOCRIPTINE ET HETEROGENEITE MOLECULAIRE DE LA PROLACTINE | |
Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy | |
PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency | |
[Pseudohypoxemia and a myeloproliferative syndrome] | |
Pseudotumor of the pituitary due to PROP-1 deletion | |
Quelles causes génétiques rechercher en présence d’un déficit en hormone de croissance ? | |
Radiochirurgie gamma-knife dans les adénomes hypophysaires secrétants | |
Radiotherapy and radiosurgery in acromegaly | |
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly | |
The role of CBP/p300 interactions and Pit-1 dimerization in the pathophysiological mechanism of combined pituitary hormone deficiency | |
Role of stereotactic radiosurgery in the management of pituitary adenomas. | |
La santé et la vie | |
The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling | |
[Serum human growth hormone assay. Comparison of six assay kits] | |
Severe fibromyalgia after hypophysectomy for Cushing's disease | |
Short-term effect of delayed-action injectable bromocriptine in macroprolactinoma. French multicenter study | |
Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study | |
[Somatostatin agonists in the treatment of acromegaly] | |
Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions | |
Successful IVF pregnancy despite inadequate ovarian steroidogenesis due to congenital lipoid adrenal hyperplasia (CLAH): a case report. | |
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly | |
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. | |
Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry | |
Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. | |
Tpit mutations reveal a new model of pituitary differentiation and account for isolated ACTH deficiency | |
Truncation of PITX2 differentially affects its activity on physiological targets. | |
An ultrarapid prognostic index in microprolactinoma surgery | |
Unilateral agenesis of internal carotid artery associated with congenital combined pituitary hormone deficiency and pituitary stalk interruption without HESX1, LHX4 or OTX2 mutation: a case report. | |
The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. | |
[Value of alpha subunit assay in pituitary pathology] | |
Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. |